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Background: Toll-like receptors (TLRs) are effector molecules expressed on the surface of ovarian cancer (OC) cells,
but the functions of the TLR2/TLR4 signaling pathways in these cells remain unclear. Melatonin (mel) acts as an
anti-inflammatory factor and has been reported to modulate TLRs in some aggressive tumor cell types. Therefore,
we investigated OC and the effect of long-term mel therapy on the signaling pathways mediated by TLR2 and
TLR4 via myeloid differentiation factor 88 (MyD88) and toll-like receptor-associated activator of interferon (TRIF) in
an ethanol-preferring rat model.
Methods: To induce OC, the left ovary of animals either consuming 10% (v/v) ethanol or not was injected directly
under the bursa with a single dose of 100 μg of 7,12-dimethylbenz(a)anthracene (DMBA) dissolved in 10 μL of
sesame oil. The right ovaries were used as sham-surgery controls. After developing OC, half of the animals received
i.p. injections of mel (200 μg/100 g b.w./day) for 60 days.
Results: Although mel therapy was unable to reduce TLR2 levels, it was able to suppress the OC-associated
increase in the levels of the following proteins: TLR4, MyD88, nuclear factor kappa B (NFkB p65), inhibitor of NFkB
alpha (IkBα), IkB kinase alpha (IKK-α), TNF receptor-associated factor 6 (TRAF6), TRIF, interferon regulatory factor 3
(IRF3), interferon β (IFN-β), tumor necrosis factor alpha (TNF-α), and interleukin (IL)-6. In addition, mel significantly
attenuated the expression of IkBα, NFkB p65, TRIF and IRF-3, which are involved in TLR4-mediated signaling in OC
during ethanol intake.
Conclusion: Collectively, our results suggest that mel attenuates the TLR4-induced MyD88- and TRIF-dependent
signaling pathways in ethanol-preferring rats with OC.
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Ovarian cancer (OC), which affects approximately 1 in
70 women, is among the most lethal gynecological ma-
lignancies and exhibits a poor prognosis when diagnosed
during the late stage (<50% with a 5-year survival rate)
[1]. Unfortunately, early-stage OC presents with no
apparent symptoms, and no effective screening tool is
currently available [2]. OC has been presumed to arise
from lesions involving the ovarian surface epithelium
(OSE) or ovarian epithelial inclusion cysts [1,2], which
exhibit morphological characteristics of the reproduct-
ive tract epithelium (or Mullerian duct). Resistance to
chemotherapy is the primary factor that hinders the
long-term treatment of OC [2], and paclitaxel resistance
has been recognized to induce recurrent OC and protu-
mor activities [3].
TLRs are cell surface sensors that can initiate path-
ways to stimulate cell proliferation and chemoresistance,
as well as recruiting immune cells to provide support for
cancer progression [4]. It has been documented that
TLR4 plays important roles in promoting the immune
escape of several human cancer cells, including OC cells
[5,6]. Furthermore, TLR4-mediated signaling is associ-
ated with the metastatic potential of tumor cells [7].
TLRs generally signal via a MyD88-dependent pathway,
leading to a proinflammatory response. MyD88-mediated
signaling promotes the early activation of NFkB, a nuclear
factor that is responsible for the production of many
proinflammatory cytokines, such as interleukin (IL)-6,
IL-8, and TNF-α and is related to the immune response,
cell adhesion, proliferation, angiogenesis, and apoptosis
[8,9]. Conversely, a MyD88-independent pathway in-
volves TRAM and, instead of MyD88, stimulates TRIF
signaling, leading to late-phase activation of NFkB and
induction of IRF3, which increases the production of
IFN and IFN-inducible gene products [10].
Because ethanol (EtOH) intake produces a variety of
co-carcinogenic and pro-inflammatory effects and seems
to positively regulate TLR2/TLR4, IkBα, NFkB, and TNF-
α [11], the combination of induced OC and EtOH intake
results in the appropriate histological and molecular pat-
terns that are needed to evaluate new chemotherapeutic
compounds. Thus, we have previously proposed a useful,
ethanol-preferring rat model for studying OC, and, not-
ably, long-term mel therapy significantly reduced OC
masses and the incidence of adenocarcinomas [12].
EtOH consumption by these animals is associated with
cumulative incidence of serous papillary carcinoma and
upregulation of Her-2-signaling pathway by OC cells [13].
Mel (N-acetyl-5-methoxytryptamine) is an indolea-
mine produced by the pineal gland, with maximal secre-
tion at night [14]. The nighttime surge of mel has been
suggested to serve as a "natural restraint" for tumor initi-
ation, promotion, and progression [15]. Mel has beenindisputably implicated as a therapeutic agent, including
in the treatment of reproductive cancers [16,17]. Due to
its versatility, mel has been recognized as having antio-
xidant, oncostatic, and immunomodulatory properties
[18,19]. Numerous reports have shown that mel modu-
lates early and late NFkB signaling during inflammation
[20,21], thus resulting in changes in the expression of
genes such as IL-1, IL-6, IL-12, and TNF-α [22]. Fur-
thermore, some cytokines (IL-2, IL-6, and IL-12) and
factors (TNF-α and IFNs) displaying immunotherapeutic
potential have been associated with mel and are under
investigation as adjuvant therapies for cancer [23,24].
Notably, the administration of mel significantly sup-
presses the expression of TLR4 and, in turn, MyD88,
cytosolic IkBα, and nuclear NFkB p65 after ischemia/re-
perfusion in rats. Taken together, the reduction of p38
MAPK, NFkB, TNF-α, and IL-6 expression occurs due
to an indirect decrease in the MyD88 protein levels [25].
Despite considerable efforts to understand the activation
of the TLR2 and TLR4 signaling pathways, the exact
mechanism(s) by which mel acts in the OC microenvir-
onment remain unclear.
To better understand this issue, the present study was
designed to investigate OC and the effect of long-term
mel therapy on the signaling pathways mediated by
TLR2 and TLR4 via MyD88 and TRIF in an ethanol-
preferring rat model.
Methods
Animals and experimental design
Eighty 60-day-old adult UChB (a model of ethanol-
preferring rats that was developed by selective breeding)
female rats weighing 200–230 g were obtained from the
Department of Anatomy, Bioscience Institute/Campus
of Botucatu, Univ Estadual Paulista (UNESP). The rats
were individually housed in polypropylene cages con-
taining laboratory-grade pine shavings as bedding and
were maintained under constant room temperature (RT;
23 ± 1°C) and lighting conditions (12-h light/dark cycle,
with the lights switched on at 6 a.m.). Filtered tap
water and standard rodent chow (3074 SIF, Purina
Ltda., Campinas, SP, Brazil) containing (by weight)
19.90% protein, 30.03% carbohydrate, 3.80% fat, and
13.36% fiber, representing 3.00 kcal/g metabolizable
energy, were provided ad libitum. All animals were
divided into two arms (n = 40/group): the EtOH group, in
which the rats were provided with access to a 10% (v/v)
ethanol solution ad libitum (free choice of water or
ethanol), and a control group, which was composed of
ethanol-naïve rats without access to ethanol. When the
ethanol-preferring rats reached 65 days of age, they
were given a choice between two bottles containing
either water or a 10% (v/v) ethanol solution ad libitum
for 15 days. The animals displaying EtOH consumption
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EtOH/kg/day) were selected according to the procedure
described by Chuffa et al. [26,27]. In this study, the pref-
erence rate associated with ethanol-seeking behavior
was approximately 70%.
After OC development (260-days-old), the animals
(n = 40) designated to receive mel (M-5250, Sigma-
Aldrich, St. Louis, MO, USA) were administered i.p.
doses of 200 μg/100 g b.w. dissolved in 0.04 mL of 95%
EtOH and then diluted in 0.3 mL of 0.9% NaCl (ve-
hicle) to a final concentration of 0.3 mg/mL. The daily
injections were administered nocturnally (between
18:30 and 19:00, Zeitgeber time (ZT) 13, Figure 1B) for
60 consecutive days (Figure 1A) [28,29].
Finally, the rats were divided into four groups (n = 20):
Group OC, composed of DMBA-induced animals that
did not consume EtOH; Group OC+ EtOH, composed of
DMBA-induced animals that consumed 10% (v/v) EtOH
during ovarian tumor development (OTD); Group OC+
Mel, composed of DMBA-induced animals that received
mel as a therapy; and Group OC+ EtOH+Mel, composed
of DMBA-induced animals that consumed 10% (v/v) EtOHFigure 1 Experimental design, OC development, and mel treatment. (
mel therapy (days). (B) Basic protocol used for daily melatonin administrati
time. ZT 13: time point of melatonin administration; ZT 22: time point of eu
age in animals receiving EtOH or EtOH + DMBA. (D) Macroscopic and histo
animals. Mel therapy efficiently reduced the tumor size but exerted no effe
ovary, bar = 50 μm). (E) The plasma mel levels (pg/mL) prior to treatment i
volume (mm3) was recorded throughout the treatments. aP < 0.05 vs. Grouduring OTD and received mel as a therapy. After these
procedures, the females were anesthetized and eutha-
nized by decapitation (during the early morning at 4 a.m.
or at ZT 22, which corresponded to the environmental
circadian time; Figure 1B) for sample collection.
Ethical statement
The use of laboratory animals in this study was approved
by the Ethical Committee of the Institute of Bioscience/
UNESP (CEEA – Permit Number: 382). The guide for the
care and use of laboratory animals, published by National
Academy of Science, was strictly followed in all expe-
riments. To minimize pain, suffering or distress during
experimentation, all of the animals were anesthetized with
ketamine (50 mg/kg) and xylazine (10 mg/kg) prior to
decapitation so that they were rendered unconscious.
Ovarian tumor induction procedure
After selection based on ethanol consumption, all of the
animals (n = 80) were anesthetized using 10% ketamine
(60 mg/kg, i.p.) and 2% xylazine (5 mg/kg, i.p.) during
the estrous phase, and the left flank region of the skinA) Timeline for EtOH intake selection, ovarian tumor induction, and
on based on ZT and corresponding to the environmental circadian
thanasia. (C) Cumulative incidence (%) of OC from 120 to 260 days of
pathological characteristics of the OC tissue in the ethanol-drinking
ct on tissue morphology (tumor = left ovary, bar = 20 μm; sham = right
nitiation (day 0) and after 30 and 60 days of treatment. (F) The tumor
p OC; bP < 0.05 vs. Group OC + EtOH.
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through the skin and the abdominal muscles was per-
formed, and the ovaries were accessed after grasping the
fat pad near the left kidney. The left ovary was injected
directly under the bursa with a single dose of 100 μg of
DMBA (Sigma Chemical Co, St Louis, MO) dissolved in
10 μL of sesame oil, which was used as the vehicle [30],
and was returned intact to the body cavity. The muscle
and skin layers were closed using a 3–0 silk suture
(Ethicon, Inc., Juarez, MX). Sham surgery was con-
ducted on the right ovary by administering only the
vehicle. An antibiotic (105 units of benzylpenicillin
potassium) was administered i.p. for prophylactic treat-
ment. Over the next 180 days, the rats were monitored,
and tumor development was observed via ultrasonog-
raphy. The ovary size (volume and diameter) was used
as a comparative parameter during OC development,
and high-grade serous papillary carcinomas were sub-
jected to treatment.
Determination of plasma mel concentrations
After blood collection (4 a.m.), mel was extracted from
plasma (n = 20 samples/group) using HPLC-grade methanol
and was separated on HPLC column (Sep-Pak Vac C-18,
reverse phase, 12.5 nm; Water Corporation, Milford,
MA, USA). Thereafter, 50 μL of the reconstituted
samples were assayed using a Coat-a-count Melatonin
ELISA Kit and were immediately read at 405 nm. The
intra-assay coefficient of variation was 4%, and all of the
samples were assayed in duplicate to avoid inter-assay
variability. All of the reagents and microtiter plates were
provided by IBL International (Hamburg, Germany). The
concentrations of mel are presented as pg/mL.
Immunohistochemistry
For immunohistochemistry, sections of OC tissue (n =
10/group) were deparaffinized in xylene based on the
areas previously identified during the morphological
characterization. Thereafter, tissue sections were micro-
waved (700–800 W) while immersed in 0.01 M sodium
citrate buffer, pH 6.0, for 3 × 5 min for antigen retrieval.
After blocking endogenous peroxidase activity with 3%
hydrogen peroxide and 97% methanol, the tissues were
incubated in 3% bovine serum albumin (BSA) for 1 h to
eliminate non-specific binding. Subsequently, OC tissue
sections were incubated in a humidified chamber over-
night at 4°C with primary antibodies (Abcam, Cambridge,
UK): rabbit polyclonal anti-TLR2 (1:100), mouse mono-
clonal anti-TLR4 (1:100), rabbit polyclonal anti-MyD88
(4 μg/ml), rabbit polyclonal anti-IkBα (1:50), rabbit
monoclonal anti-IKKα (1:50), rabbit polyclonal anti-
NFkB p65 (1:100), rabbit monoclonal anti-TRAF6
(1:50), rabbit polyclonal anti-TRIF (1:100), and rabbit
monoclonal anti-IRF3 (1:100). After immunoreaction, theslides were washed in TBS-T buffer and incubated with
secondary antibody (Polymer Anti-Mouse IgG or Anti-
Rabbit - DAKO ® CYT) at RT for 1 h. Then, the slides
were reacted with chromogen diaminobenzidine (DAB;
Sigma, St. Louis, MO, USA) for 5 min. Finally, tissue sec-
tions were counterstained with hematoxylin. Negative
controls were generated by omitting the primary antibody.
The IHC results were analyzed by two pathologists under
a Zeiss Axiophot II microscope (Carl Zeiss, Oberkochen,
Germany) based on the levels of staining intensity, which
were scored as absent (0), weak (+), moderate (++), or
strong (+++) immunoreactivity.
Immunofluorescence assays
Epithelial OC cells were cultured, washed with phosphate-
buffered saline (PBS; sodium chloride, potassium chloride,
dihydrogen phosphate, and disodium hydrogen phos-
phate), fixed in 4% paraformaldehyde for 10 min, and
permeabilized with PBS at RT. Nonspecific binding sites
were blocked with 1% BSA for 60 min. The samples
were incubated with the anti-NFkB p65 primary rabbit
polyclonal antibody (dilution 1:100, ab7970, Abcam,
Cambridge, MA, USA) overnight at 4°C, followed by a
secondary polyclonal anti-rabbit IgG conjugated to
FITC (1:200, sc-2012, Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA) for 1 h at RT. Nuclei were stained
with 6-diamidino-2-phenylindole (DAPI, 5 min) at RT.
Primary and secondary antibodies were diluted in blocking
buffer (1% BSA). For negative immunolabeling, no pri-
mary antibody was added. The immunopositive cells
were analyzed using a fluorescence microscope (Zeiss
Axiophot II, Oberkochen, Germany) at 40× magnifica-
tion (immunofluorescence: excitation 590 nm, emission
filter 650 nm) and for DAPI staining (excitation 365 nm,
emission filter 435–485 nm). The quantification of relative
fluorescence in the merged images was performed using
Image J software.
Immunoblotting and protein quantification
After mel therapy, the abdominal cavity was opened, the
OC samples were rapidly removed, and 100-mg tissue
samples were frozen in liquid nitrogen and stored at −80°C.
The tissues were microdissected (only areas containing
serous papillary tumors were obtained from the ovaries)
and homogenized using 10× RIPA lysis buffer (Pierce
Biotechnology, Rockford, IL, USA) supplemented with a
cocktail of protease inhibitors (Sigma Chemical Co.). Ali-
quots of 1:10 (v/v) dilutions of Triton X-100 were added
to the homogenates, and samples were placed on dry ice
with agitation for 2 h to improve extraction. The lysates
were centrifuged at 21,912 g for 20 min at 4°C to re-
move insoluble material, and total protein was measured
through colorimetric determination. All protein samples
were dissolved in 1.5X Laemmli buffer and used for
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The same amount of protein (70 μg) was loaded per well
and resolved on preformed 4-12% acrylamide gradient
gels (Amersham Biosciences, Uppsala, Sweden) using a
Tris-glycine running buffer electrophoresis system
(60 mA for 2 h). After electrophoresis, total protein
samples were electro-transferred (200 mA for 1.5 h)
to nitrocellulose membranes in Tris-glycine-methanol
buffer. Kaleidoscope Prestained Standards (Bio-Rad,
Hercules, CA, USA) were used as molecular weight
markers. Thereafter, the membranes were blocked with
TBS-T solution containing 3% BSA at RT for 60 min
and then incubated at 4°C overnight with the following
antibodies (1:500 in 1% BSA): TLR2, TLR4, MyD88,
IkBα, IKK-α, NFkB p65, NFkB p50, TRAF6, TRIF, and
IRF-3 (Abcam, Cambridge, UK). This treatment was
followed by 3 × 5 min washes in TBS-T solution and
incubation for 2 h at RT with rabbit or mouse HRP-
conjugated secondary antibodies (diluted 1:1000 in 1%
BSA; Sigma-Aldrich Chemicals, St. Louis, MO, USA).
After sequential washes in TBS-T, the signals were de-
veloped using an ECL detection kit (Thermo Scientific).
Immunoreactive bands were obtained from individual
blots of 10 rats/group using image analysis software
(NIS-Elements, Advanced Research, Nikon). β-actin
(cytosolic extract) and Lamin B1 (nuclear extract) were
used as endogenous positive controls, and the results
were expressed as the means ± SD. The protein concen-
trations are presented as the percentage of the optical
density (band intensity-background) relative to the posi-
tive control.
Subcellular fractionation
Cytosolic and nuclear extracts were obtained from OC
cells using NE-PER nuclear and cytoplasmic extraction
reagents (Thermo Scientific, Rockford, IL) according to
the manufacturer's instructions. Equivalent amounts of
the cytoplasmic and nuclear fractions were boiled in
SDS lysis buffer for Western blot analysis. To ensure no
cross-contamination occurred, specific biomarkers for
the cytosolic and nuclear fractions were used.
Elisa assays
The concentrations of IFN-β (cat. R1F00), TNF-α (cat.
RTA00), IL-6 (cat. R6000B), and IL-8 (cat. D8000C) were
measured using equal amounts of the supernatants of
the OC samples. Commercial coated-a-coat rat ELISA kits
were provided by R&D Systems (Minneapolis, MN, USA).
Statistical analysis
The values are presented as the means ± standard deviation
(SD), and data analyses were performed using two-way
analysis of variance (ANOVA) for two independent factors
(EtOH consumption and mel treatment). Significant resultswere subjected to post-hoc analysis using Tukey's test,
and significance was set at P < 0.05. GraphPad Instat
Version 4 statistical software and Sigma Plot Version
12.5 graphing software were used.
Results
OC development and mel therapy
Although the cumulative OC incidence was slightly
increased after the combination of DMBA with EtOH
intake (Figure 1C), no apparent difference in the OC
phenotype was observed following EtOH consumption.
To confirm the effect of mel on this rat model of OC,
macroscopic and microscopic analyses were frequently
performed (Figure 1D); although mel therapy reduced
the size of the OC, their serous papillary aspects with
markedly pleomorphic nuclei were unchanged after
mel treatment (Figure 1D). Notably, we measured the
plasma mel levels to validate its concentration during
long-term therapy in animals consuming or not con-
suming EtOH and exhibiting OC. As expected, a high
concentration of mel was found in both the OC +Mel
and OC + EtOH +Mel groups after 30- and 60-day
treatment (Figure 1E). As a consequence of mel treat-
ment, the tumor volume was reduced after 30 days (by
about 29% and 34.8% for the OC and OC + EtOH
groups, respectively; Figure 1F) and 60 days (by about
48% and 54.2% for the OC and OC + EtOH groups,
respectively; Figure 1F).
Mel differentially regulated the expression of TLR2, TLR4,
and MyD88 in OC of EtOH-preferring rats
In response to mel treatment, TLR2 expression and im-
munostaining were increased (1.22-fold increase vs. OC)
in the epithelium of serous papillary carcinoma (Table 1,
Figure 2A, B, M, N). However, the combination of EtOH
with mel caused a significant downregulation of TLR2
(1.54- and 1.16-fold reduction vs. OC +Mel and OC +
EtOH, respectively, Table 1, Figure 2B-D, M, N). In con-
trast, mel therapy negatively regulated TLR4 (1.23-fold
reduction vs. OC; Table 1, Figure 2E, F, M, O) and
MyD88 (1.30-fold reduction vs. OC; Table 1, Figure 2I, J,
M, P) in these cells. The effects of mel therapy and/or
EtOH intake on the TLR2- and TLR4-induced MyD88-
mediated signaling pathways are presented in Figure 2Q.
The downregulation of NFkB signaling is enhanced by
Mel regardless of EtOH intake
The involvement of the NFkB pathway during mel or
EtOH treatment was determined in cytosolic and nu-
clear extracts of OC cells by analyzing the expression of
IKK-α, IkBα, and NFkB p65/p50. Notably, IKK-α and
IkBα were downregulated by mel therapy (1.25- and
1.37-fold reduction vs. OC; Table 1, Figure 3A, B, E, F
and Figure 4A-C). In contrast, IKK-α was upregulated
Table 1 Scoring of immunohistochemical staining of OC
cells
Treatments
OC OC +Mel OC + EtOH OC + EtOH +Mel
TLR2 + ++ + 0
TLR4 +++ + +++ ++
MyD88 ++ 0 ++ +
IKK-α + 0 ++ ++
IkBα ++/+++ 0/+ ++/+++ 0/+
NFkB p65 +++ 0/+ +++ ++
TRAF6 ++ + + +
TRIF +/++ + +/++ +
IRF3 +++ ++ +++ ++/+++
OC staining were interpreted by pathologist visual scoring as 0 (no staining),
+ (<10% of carcinoma staining), ++ (10-50% of carcinoma staining), or +++ (>50%
of carcinoma staining). N = 10 animals/group. Five selected OC sections were
analyzed per animal.
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1.35-fold vs. OC and OC +Mel, respectively; Table 1,
Figure 3C, D and Figure 4A, B). The combination of mel
with EtOH reduced IkBα expression (1.42-fold decrease
vs. OC + EtOH; Table 1, Figure 3G, H and Figure 4A, C),
similar to mel treatment alone. As expected, the epithe-
lial OC cells were NFkB p65-positive in the cytoplasm
and nucleus (Table 1, Figure 3I) and became strongly
immunopositive after EtOH intake (Table 1, Figure 3K).
Surprisingly, mel alone induced the downregulation of
cytosolic NFkB p65 and p50 (0.2- and 0.25-fold reduc-
tion, respectively, vs. OC; Figure 4A, D, E) and nuclear
NFkB p65 (0.18-fold reduction vs. OC; Figure 4A, F, G);
presumably, a negligible amount of the NFkB p65/p50
complex was translocated as a dimer to the nucleus. In
addition, mel satisfactorily downregulated NFkB p65 in
animals with OC that consumed EtOH (Figure 3L and
Figure 4A, D, F, G). Briefly, Figure 4H shows the positive
or negative regulatory effects of mel or EtOH on NFkB
activation in the OC cells "in vivo". Immunofluorescence
assays revealed the expression level and localization of
cytosolic/nuclear NFkB p65 in OC cells. Mel therapy
efficiently resulted in downregulation of NFkB p65
expression (Figure 4I, J; level of fluorescence reduced
from 97% ± 10.2 (OC) to 66% ± 14.6 (OC +Mel)). In
contrast, the levels of nuclear and cytosolic NFkB p65
were significantly increased by EtOH intake and were
drastically decreased after mel treatment (Figure 4K, L;
level of fluorescence 168% ± 19.2 (OC + EtOH) vs. 84% ±
11.6 (OC + EtOH +Mel)).
Mel therapy attenuated TRIF-dependent signaling in OC
of EtOH-preferring rats
To investigate the effects of mel on the MyD88-independent
signaling pathway, the levels of TRAF6, TRIF, and IRF3were measured in OC tissues. Interestingly, mel therapy
downregulated TRAF6 expression (1.24-fold reduction
vs. OC; Table 1, Figure 5A, B, M, N), and no significant
difference (P < 0.05) was observed following EtOH intake
or the combination of EtOH and mel treatment (Table 1,
Figure 5C, D, M, N). Unexpectedly, mel significantly at-
tenuated the MyD88-independent TLR2-/TLR4-mediated
signaling pathway by reducing the expression of TRIF and
IRF3 in serous papillary OC (1.30- and 1.35-fold reduction
vs. OC; Table 1, Figure 5E, F, I, J, M, O, P); thus, mel acted
as a repressor of the non-canonical TLR2/TLR4-mediated
signaling pathway. Furthermore, mel therapy dramatically
reduced the expression of TRIF and IRF3 during EtOH
intake (1.55- and 1.28-fold reduction, respectively, vs.
OC + EtOH; Figure 5G, H, K, L, M, O, P). As shown in
Figure 5Q, mel negatively regulated TRAF6, TRIF, and
IRF3 in OC cells and was considered to alter both early
and late-phase NFkB translocation and IFN-β production.
The IFN-β, TNF-α, and IL-6 levels were reduced after Mel
therapy but not in the presence of EtOH
The concentrations of IFN-β, TNF-α, and IL-6 in the
OC group were 100.2 ± 12.0 pg/mL, 121.7 ± 11.8 pg/mL
and 147.3 ± 16.2 pg/mL, respectively. Treatment with
mel significantly attenuated the increased levels of these
proinflammatory cytokines in OC tissue (37.8%, 43.2%, and
44.7% of Group OC, respectively; P < 0.01) (Figure 6A-C).
In addition, the IL-8 levels were unchanged for all treat-
ments (Figure 6D). Finally, EtOH consumption in asso-
ciation with OC was unable to alter the levels of these
inflammatory cytokines (P > 0.05, Figure 6A-D).
Discussion
We recently demonstrated that long-term mel therapy
efficiently reduced the OC size and the incidence of
adenocarcinoma in ethanol-preferring animals [12]. Al-
though EtOH consumption has been assumed to inhibit
plasma mel levels [26], our data showed that both mel-
treated groups maintained their physiological levels at
night, even in the presence of EtOH. Importantly, the
present study revealed that mel negatively regulates the
TLR4-mediated, but not TLR2-mediated signaling path-
way in OC of ethanol preferring-rats. In addition, the TRIF
signaling pathway was downregulated by mel therapy.
Specifically in OC, a variety of TLRs (including TLR2,
TLR3, TLR4, and TLR5) are highly expressed in neoplas-
tic ovarian epithelial cells, indicating poor prognosis
[31]. In OC cells, TLR4 has been shown to perform a
protumor function and to hamper the efficacy of cancer
therapies (e.g., paclitaxel) [3]; conversely, mel signifi-
cantly reduces TLR4 expression in this rat OC model.
Although studies of the role of mel in the anti-tumoral
suppression of TLR4/NFkB are scarce, in vitro data showed
that mel promotes the inhibition of TLR4-mediated
Figure 2 Immunohistochemical localization and Western blot analysis of TLR2, TLR4 and MyD88 in serous papillary ovarian carcinoma.
The immunoreactivity for TLR2 was moderate in the surface epithelium of OC +Mel (B) compared to OC animals (A) (arrows). Weak immunoreactivity
for TLR2 was found in OC + EtOH animals (C) but was more pronounced in OC + EtOH +Mel animals (D). TLR4 immunoreactivity was intense in the
surface epithelium, but not in the stroma, of the OC (E) and OC + EtOH groups (G) (arrows). Weak immunoreactivity for TLR4 was observed in the OC
+Mel group (F) (arrow), and moderate TLR4 reaction was detected in the epithelium of the OC + EtOH +Mel group (H) (arrow). Moderate MyD88
reaction was observed in the epithelium of the OC group (I) (arrow), in contrast to very weak immunoreactivity for MyD88 in the OC +Mel group
(J) (arrow). The OC + EtOH (K) and OC + EtOH +Mel groups (L) displayed moderate and weak signals for MyD88, respectively (arrows). Bar = 20 μm.
Negative controls were used. (M) Representative TLR2, TLR4, and MyD88 expression profiles in extracts (70 μg protein) pooled from 10 samples/group
(upper panel). (N–P) Extracts obtained from individual rats were used for densitometric analysis of the TLR2, TLR4, and MyD88 levels following
normalization to the β-actin. All results are expressed as the means ± SD (n = 10 animals/group). aP < 0.05 vs. OC; bP < 0.05 vs. OC +Mel and cP < 0.05
vs. OC + EtOH. (Q) Schematic representation of the TLR2 and TLR4 signaling pathways via MyD88 and IRAK intracellular cascade, leading to NFkB
activation, in a typical ovarian carcinoma cell. TLR2 is upregulated by mel and downregulated by EtOH + Mel, whereas TLR4 is downregulated
by mel. Mel therapy also negatively regulates MyD88 expression. mel: melatonin; EtOH: ethanol; IRAK: IL-1 receptor-associated kinase; TRAF6:
TNF receptor-associated factor 6; TAK1: TGF-B-activated kinase 1; NFkB: nuclear factor kappa B.
Chuffa et al. BMC Cancer  (2015) 15:34 Page 7 of 13inflammatory genes via MyD88-dependent signaling
pathway [32], and that mel acts as a TLR4/MyD88 an-
tagonist [33]. Due to its anti-inflammatory properties,mel may be considered as an additional therapy for cer-
tain tumors. Interestingly, our results indicated for the
first time that mel upregulated TLR2 and that the
Figure 3 Immunohistochemical localization of IKK-α, IkBα, and NFkB in serous papillary ovarian carcinoma. Immunoreactivity for IKK-α
was weak in the OC group (A) and absent from the OC +Mel group (B). Moderate reaction for IKK-α was detected in the OC + EtOH (C) and
OC + EtOH +Mel animals (D). Immunoreactivity for IkBα was moderate to high in the surface epithelium of the OC (E) and OC + EtOH groups
(G) and was weak in the OC +Mel (F) and OC + EtOH +Mel groups (H). Strong immunoreactivity for NFkB was detected in the epithelium of the
pappilae of the OC (I) and OC + EtOH groups (K). The OC +Mel (J) and OC + EtOH +Mel groups (L) displayed weak and moderate signals for
NFkB, respectively (arrows; Bar = 20 μm).
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of TLR2. These results demonstrate that distinct from
its effect on other tissues and under other conditions
[11,34], EtOH alone reduces the expression of TLR2 in
OC cells. Future studies exploring the effect of mel on
genetic TLR2 and TLR4 knockout mice are required to
further understand the molecular mechanism(s) by
which mel regulates inflammation in OC. The activation
of the MyD88 signaling pathway induces tumor cell sur-
vival, proliferation, and chemoresistance [3,5,6]. Many
studies have reported the ability of mel to modulate the
MyD88-dependent signaling pathway [25,32]. MyD88 is
a critical adaptor that is directly involved in the TLR4-
mediated expression of inflammatory genes [35]. The
present study showed that the level of MyD88 was sig-
nificantly reduced following mel therapy in OC. These
results are in agreement with others that showed that
mel effectively suppressed the elevation of MyD88 ex-
pression in several disorders associated with inflamma-
tory responses [25,32,36]. Conversely, EtOH intake is
associated with increased expression of MyD88, mainly
in the liver of females exposed to higher doses of EtOH
(6 g EtOH/kg b.w.) [37]. Although MyD88 expression
appears to be unaffected by EtOH intake, mel therapysignificantly inhibited the MyD88-dependent signaling
pathway in experimental OC.
NFkB plays a critical role in the TLR4-mediated signal-
ing pathway in tumor cells. Under unstimulated condi-
tions, NFkB is retained in the cytoplasm by binding to
IkB. After phosphorylation by IKK, IkB is degraded via the
proteasome, and the NFkB subunits p65 and p50 translo-
cate to the nucleus [38]. According to an earlier report in-
volving serous papillary OC, the mechanisms underlying
long-term survival and chemotherapy resistance are dir-
ectly associated with NFkB signaling [39]. The present
study showed that mel significantly reduced the expres-
sion of IKK-α, IkBα, and NFkB p50/p65 in OC cells. Fur-
thermore, the NFkB subunit p65 was reduced in cytosolic
and nuclear extracts, demonstrating that mel may act on
mechanisms regulating gene expression and nuclear trans-
location of NFkB p65. Most of the effects of NFkB activa-
tion on tumor cells have been linked to the upregulation
of antiapoptotic protein expression, cell proliferation, and
proinflammatory cytokine production [5,40], which may
enable these cells to progress and metastasize. Thus, we
propose that the inhibitory effect of mel on the TLR4-
mediated signaling pathway might be partially attributed
to the repression of NFkB activation in OC.
Figure 4 Western blot analysis of IKK-α, IkBα, and NFkB in serous papillary ovarian carcinoma. Representative protein profiles (A) of
cytosolic and nuclear extracts (70 μg protein) pooled from 10 samples/group. (B–G). Extracts obtained from individual rats were used for
densitometric analysis of the protein levels following normalization to β-actin or LaminB1. The results are expressed as the means ± SD (n = 10
animals/group). aP < 0.05 vs. OC; bP < 0.05 vs. OC +Mel; and cP < 0.05 vs. OC + EtOH. (H) The canonical pathway that leads to the activation of
NFkB after a ligand binds to its specific receptor. Internal signaling results in the phosphorylation of IkBα by the IKK complex, leading to the
ubiquitylation and degradation of NFkB via proteasome. The NFkB p65/p50 complex translocates to the nucleus to initiate the transactivation of
target genes related to the inflammatory process. Mel induces the downregulation of IKK-α, IkBα, and NFkB p65/p50, whereas EtOH consumption
upregulates IKK-α and NFkB p65. (I-L) Merged images of NFkB p65 immunofluorescence and DAPI nuclear staining in the OC (I), OC +Mel (J),
OC + EtOH (K), and OC + EtOH +Mel groups (L); details of cytosolic/nuclear staining (Alexafluor®488, Bar = 10 μm). EtOH: ethanol; mel: melatonin;
IKK-α: inhibitor of NFkB kinase subunit alpha; IkBα: inhibitor of NFkB subunit alpha; NFkB p65: NFkB subunit p65 (RelA); NFkB p50: NFkB subunit p50.
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lecular effect of EtOH on OC, chronic EtOH intake
caused an elevation in the IKK-α and NFkB p65 levels in
animals bearing OC without affecting upstream mole-
cules. In these animals, mel therapy induced the down-
regulation of NFkB p65 expression but exerted no effect
on the IKK-α levels. Indeed, EtOH alone exerts immu-
nomodulatory effects and induces alterations in down-
stream TLR signaling in many target organs, such as the
liver, the brain, and the gastric mucosa [41,42]. These
alterations include upregulation of specific cytokines and
inflammatory mediators by activating IKKs, MAPKs, and
NFkB [42]. Furthermore, TLR4 receptors were reported
to be involved in the ethanol-mediated inflammatory
response because the blockade of TLR4 abolishes theproduction of inflammatory mediators and cell death.
Although acetaldehyde appears to severely alter TLR4
signaling, the underlying mechanisms by which acetalde-
hyde targets TLR4 are unknown [43]. Based on our data,
we suggest that EtOH intake may affect only some mole-
cules downstream of TLR4 in OC cells, such as the high
activity of NFkB p65. Furthermore, EtOH intake exerted
no influence on the expression of NFkB-regulated pro-
inflammatory cytokines.
TRIF, another adaptor molecule of TLRs, is respon-
sible for the regulation of MyD88-independent pathways
[44]. TRIF signals the downstream kinases TBK1 and
IKK, leading to phosphorylation of IRF3 and the conse-
quent production of IFNs and IFN-inducible genes [45].
In particular, TRIF/IRF3-dependent signaling is thought
Figure 5 Immunohistochemical localization and Western blot analysis of TRAF6, TRIF, and IRF3 in serous papillary ovarian carcinoma.
The immunoreactivity for TRAF6 was moderate in the OC group (A) and weak in the OC +Mel group (B). The OC + EtOH (C) and OC + EtOH +
Mel groups (D) displayed weak immunostaining for TRAF6 (arrow). The immunoreactivity for TRIF was enhanced in the epithelium of the OC
(E) and OC + EtOH groups (G), but mel therapy resulted in weak reaction for TRIF in the OC +Mel (F) and OC + EtOH +Mel groups (H). Strong
immunoreactivity for IRF3 was observed in the animals from the OC (I) and OC + EtOH groups (K), in contrast to the moderate to high reactions
in the surface epithelium of the OC +Mel (J) and OC + EtOH +Mel groups (L) (arrow). Bar = 20 μm. Negative controls were used. (M) Representative
TRAF6, TRIF, and IRF3 expression profiles in extracts (70 μg protein) pooled from 10 samples/group (upper panel). (N–P) Extracts obtained from
individual rats were used for densitometric analysis of the TRAF6, TRIF, and IRF3 levels following normalization to a loading control (β-actin). All
results are expressed as the means ± SD (n = 10 animals/group). aP < 0.05 vs. OC; cP < 0.05 vs. OC + EtOH. (Q) Schematic representation of TLR
signaling. MyD88 acts as an essential TIR domain-containing adaptor for the induction of inflammatory cytokines in all TLR subtypes (canonical
pathway). In the TLR4-mediated signaling pathway, the TIR domain-containing adaptor TRIF stimulates a MyD88-independent pathway (non-canonical
pathway). This signal leads to the activation of IRF3 via TBK1 and IKKƐ/IKKi, facilitating the nuclear translocation of IRF3, which activates the expression
of inflammatory factor-related target genes (e.g., IFN-β). Treatment with mel induces the downregulation of TRAF6, TRIF, and IRF3. mel: melatonin;
TRAF6: tumor necrosis factor receptor-associated factor 6; TRIF: TIR domain-containing adaptor; TBK-1: TANK-binding kinase 1; IRF3: interferon regulatory
factor 3; IFN-β: interferon β.
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Figure 6 ELISA assays of the IFN-β (A), TNF-α (B), IL-6 (C), and IL-8(D) levels. Supernatants of ovarian samples (n = 20/group) displaying
papillary carcinoma were assessed 60 days after the final dose of mel. aP < 0.01 vs. OC. IFN-β: interferon-β; TNF-α: tumor necrosis factor alpha; IL-6:
interleukin-6; IL-8: interleukin-8. All results are expressed as the means ± SD. Two-way ANOVA followed by Tukey test was performed.
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region termed the effector-driving site that recruits
TRAF, resulting in the activation of IRF3 and NFkB [46].
The present study showed that TRAF6, TRIF, and IRF3
were markedly increased in OC and that mel therapy
inhibited their expression. Recent studies have eluci-
dated the protective effect of mel on the ischemia/re-
perfusion-injured liver [25] and on lipopolysaccharide
(LPS)-stimulated macrophages by reducing TRIF and
IRF3 expression [32]. In EtOH-preferring animals bear-
ing OC, the expression of TRIF and IRF3 was similar to
that of the OC group, and mel significantly repressed
the expression of these factors. It has been assumed that
alcoholism induces an inflammatory process at various
levels, depending on the amount of EtOH consumed
and the specific tissue [47]. This process may include
the production of proinflammatory cytokines that are
primarily stimulated by the TLR4/TRIF/IRF3-dependent
signaling pathway [47]. Specifically in OC cells, mel
therapy led to the downregulation of TRIF and IRF3.
The OC microenvironment is characterized by a dra-
matic increase in immunosuppressive cytokines, such as
TNF-α and IL-6 [46]. These cytokines activate other in-
flammatory molecules that are capable of recruiting
macrophages and dendritic cells (DCs) to the tumor site;
these cells further contribute to angiogenesis, tumor
growth, and metastasis [48]. Moreover, high levels of
anti-inflammatory cytokines and related factors (e.g.,TGF-β and VEGF) have been found in OC ascites [49].
Interestingly, we showed a significant reduction in IFN-
β, TNF-α, and IL-6 expression in OC after mel therapy.
By activating T helper (Th)-1 lymphocytes, mel en-
hances the production of cytokines such as IL-2, IL-6,
IL-12, and IFNs [50], demonstrating its beneficial ef-
fects on immune cell modulation. In addition, the anti-
inflammatory actions of mel are mediated by multiple
mechanisms, including a reduction in the levels of pro-
inflammatory cytokines and chemokines (IFNs, TNF-α,
IL-6, −8, and −12) and an increase in the levels of anti-
inflammatory cytokines (IL-10 and IL-1 antagonist). In
OC cells, the immunomodulatory properties of mel
may aid in inhibiting tumor cell growth and survival.Conclusions
In summary, this study emphasizes the cross-talk be-
tween the TLR system and mel in ethanol-preferring rats
with OC. Although long-term mel therapy exerts no
influence on TLR2 signaling, it may modulate the TLR4-
signaling pathway in a MyD88- and TRIF-dependent
manner, thereby dampening the inflammatory process
induced by OC. Although EtOH alone did not promote
additional inflammation in the OC microenvironment,
mel therapy efficiently reduced the levels of important
inflammatory factors (IkBα, NFkB p65, TRIF, and IRF-3)
during EtOH intake. These findings suggest a basis for
Chuffa et al. BMC Cancer  (2015) 15:34 Page 12 of 13the therapeutic use of melatonin as a possible adjuvant
in association with other anti-cancer therapeutic drugs.
Summary statement
Melatonin therapy attenuates the TLR4 signaling path-
way in a MyD88- and TRIF-dependent manner, damp-
ening the inflammatory process induced by OC in
a preclinical model of ovarian carcinogenesis. These
findings suggest a basis for the therapeutic use of mela-
tonin as an adjuvant.
Clinical perspectives
 TLR4-mediated signaling is associated with the
immune escape of ovarian cancer cells, and
inhibition of specific pro-inflammatory cytokines
represents a highly important therapeutic strategy.
 Melatonin, an anti-inflammatory and immunomodu-
latory indoleamine, modulated the TLR4 signaling
pathway, ultimately reducing the expression of
inflammation-related mediators in these ovarian
cancer cells, which serve as a novel and interesting
preclinical model of ovarian cancer.
 These findings suggest a basis for the therapeutic
use of melatonin as a possible adjuvant in
association with other anti-cancer drugs under
investigation in ongoing clinical studies.
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